MultiplexDX International

MultiplexDX is a biotechnology company developing technologies for personalized molecular diagnostics, with a focus on accurate, quantitative and accessible testing for cancer. Its work combines diagnostic products, research and development, and services for laboratories and researchers. The company’s offerings include Multiplex 8+, a breast cancer diagnostic test intended to support personalized treatment decisions and assessment of therapy response, and vDetect COVID-19, an IVD-certified RT-qPCR test for detecting SARS-CoV-2 genetic material in nasopharyngeal swabs for diagnostic laboratory use.

MultiplexDX also provides custom oligonucleotide synthesis, RNA sequencing, RNA FISH, next-generation sequencing and bioinformatics, as well as diagnostics for other infectious diseases. Its research projects include work on improving Alzheimer’s disease diagnostics. Researchers and institutions use its custom fluorescently labelled oligonucleotides and sequencing adapters for applications such as screening and RNA library preparation.

MultiplexDX reports collaborations with academic and medical organizations and has received an European Innovation Council Accelerator grant. The company also highlights quality management and achieved ISO 9001:2015 certification in 2024